Clinical Trials Browser

Phase 1 × Breast Neoplasms × sapanisertib × Clear all

NCT02619669 2020-03-12

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms